Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment-Reference-Cited by-同舟云学术

Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment

Published:2019-11 Issue:11 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Woodburn Kathryn W.¹,Clemens L. Edward¹,Jaynes Jesse²,Joubert Lydia-Marie³⁴,Botha Alfred³,Nazik Hasan⁵⁶,Stevens David A.⁵⁶

Affiliation:

1. Riptide Bioscience, Inc., Vallejo, California, USA

2. Integrative Biosciences, College of Agriculture, Environment and Nutrition Sciences, Tuskegee University, Tuskegee, Alabama, USA

3. Microbiology Department, Stellenbosch University, Stellenbosch, South Africa

4. Central Analytical Facilities, Stellenbosch University, Stellenbosch, South Africa

5. California Institute for Medical Research, San Jose, California, USA

6. Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California, USA

Abstract

Recurrent vulvovaginal candidiasis (RVVC) is a widespread chronic infection that has a substantial negative impact on work and quality of life. The development of antimicrobial resistance and biofilm formation are speculated to contribute to Candida pathogenicity and treatment ineffectiveness. Designed antimicrobial peptides (dAMPs) are chemically modified from endogenous antimicrobial peptides that provide the first line of defense against pathogens.

Funder

DOD | United States Army | MEDCOM | Congressionally Directed Medical Research Programs

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02690-18

Reference43 articles.

1. Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA

2. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine

3. Recurrent vulvovaginal candidiasis